Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis

IF 3 Q2 SUBSTANCE ABUSE
Jeremy W. Luk, Nghiem B. Ha, Amy M. Shui, Hannah R. Snyder, Steven L. Batki, Michael J. Ostacher, Alexander Monto, Robert J. Wong, Ramsey Cheung, Priti Parekh, William Hua, D. Andrew Tompkins, Taylor Fakadej, Christina G. Haight, Meimei Liao, Mandana Khalili, Derek D. Satre
{"title":"Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis","authors":"Jeremy W. Luk,&nbsp;Nghiem B. Ha,&nbsp;Amy M. Shui,&nbsp;Hannah R. Snyder,&nbsp;Steven L. Batki,&nbsp;Michael J. Ostacher,&nbsp;Alexander Monto,&nbsp;Robert J. Wong,&nbsp;Ramsey Cheung,&nbsp;Priti Parekh,&nbsp;William Hua,&nbsp;D. Andrew Tompkins,&nbsp;Taylor Fakadej,&nbsp;Christina G. Haight,&nbsp;Meimei Liao,&nbsp;Mandana Khalili,&nbsp;Derek D. Satre","doi":"10.1111/acer.15500","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Alcohol use disorder (AUD) treatment can help improve clinical outcomes among patients with alcohol-associated cirrhosis but is underutilized. Among socioeconomically disadvantaged patients with alcohol-associated cirrhosis, we examined rates of lifetime and past 12-month AUD treatment utilization and associated demographic and clinical characteristics.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Racial/ethnically diverse patients with alcohol-associated cirrhosis who had at least one hepatology clinic visit in the prior 6 months were recruited from three Northern California medical centers serving veterans and safety-net populations. Participants self-reported their AUD treatment utilization, liver disease quality of life (LDQoL), history and current symptoms of anxiety and depression, and problematic drinking as measured by the Alcohol Use Disorders Identification Test (AUDIT). Clinical measures including liver disease severity were captured from medical records.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 196 participants, the majority were male (88%) with a mean age of 62 years. Two-thirds of participants (67%) reported ever utilizing AUD treatment and 32% reported utilizing AUD treatment in the past 12 months. Compared with those who did not utilize AUD treatment, participants who utilized lifetime or past 12-month AUD treatment were younger, had lower LDQoL scores, and had higher scores on current symptoms of anxiety, depression, and problematic drinking. In multivariable analyses, the odds of ever utilizing pharmacological treatment alone or both behavioral and pharmacological treatment (vs. none) were lower with older age or higher LDQoL, and higher among those with a history of anxiety/depressive disorder. For past 12-month treatment utilization, odds were lower with older age, and higher among those with current clinically significant anxiety/depression or problematic drinking.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Patients with alcohol-associated cirrhosis who were younger or had anxiety/depression and problematic drinking were more likely to utilize AUD treatment. To improve AUD treatment utilization, targeted outreach to patients less likely to receive care and the provision of integrated ALD and AUD treatment is warranted.</p>\n </section>\n </div>","PeriodicalId":72145,"journal":{"name":"Alcohol (Hanover, York County, Pa.)","volume":"49 1","pages":"244-255"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcohol (Hanover, York County, Pa.)","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/acer.15500","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Alcohol use disorder (AUD) treatment can help improve clinical outcomes among patients with alcohol-associated cirrhosis but is underutilized. Among socioeconomically disadvantaged patients with alcohol-associated cirrhosis, we examined rates of lifetime and past 12-month AUD treatment utilization and associated demographic and clinical characteristics.

Methods

Racial/ethnically diverse patients with alcohol-associated cirrhosis who had at least one hepatology clinic visit in the prior 6 months were recruited from three Northern California medical centers serving veterans and safety-net populations. Participants self-reported their AUD treatment utilization, liver disease quality of life (LDQoL), history and current symptoms of anxiety and depression, and problematic drinking as measured by the Alcohol Use Disorders Identification Test (AUDIT). Clinical measures including liver disease severity were captured from medical records.

Results

Among 196 participants, the majority were male (88%) with a mean age of 62 years. Two-thirds of participants (67%) reported ever utilizing AUD treatment and 32% reported utilizing AUD treatment in the past 12 months. Compared with those who did not utilize AUD treatment, participants who utilized lifetime or past 12-month AUD treatment were younger, had lower LDQoL scores, and had higher scores on current symptoms of anxiety, depression, and problematic drinking. In multivariable analyses, the odds of ever utilizing pharmacological treatment alone or both behavioral and pharmacological treatment (vs. none) were lower with older age or higher LDQoL, and higher among those with a history of anxiety/depressive disorder. For past 12-month treatment utilization, odds were lower with older age, and higher among those with current clinically significant anxiety/depression or problematic drinking.

Conclusions

Patients with alcohol-associated cirrhosis who were younger or had anxiety/depression and problematic drinking were more likely to utilize AUD treatment. To improve AUD treatment utilization, targeted outreach to patients less likely to receive care and the provision of integrated ALD and AUD treatment is warranted.

Abstract Image

在一项酒精相关性肝硬化患者的多中心研究中,与酒精使用障碍治疗利用相关的人口学和临床特征
背景:酒精使用障碍(AUD)治疗有助于改善酒精相关性肝硬化患者的临床结果,但未得到充分利用。在社会经济条件不利的酒精相关性肝硬化患者中,我们检查了终生和过去12个月AUD治疗使用率以及相关的人口统计学和临床特征。方法:从北加州三个为退伍军人和安全网人群服务的医疗中心招募了种族/民族多样化的酒精相关性肝硬化患者,这些患者在过去6个月内至少有一次肝病门诊就诊。参与者自我报告他们的AUD治疗使用情况、肝病生活质量(LDQoL)、焦虑和抑郁的历史和当前症状,以及通过酒精使用障碍识别测试(AUDIT)测量的问题性饮酒。从医疗记录中获取包括肝病严重程度在内的临床指标。结果:196名参与者中,大多数为男性(88%),平均年龄为62岁。三分之二的参与者(67%)报告曾使用AUD治疗,32%报告在过去12个月内使用AUD治疗。与未使用AUD治疗的参与者相比,使用终身或过去12个月AUD治疗的参与者更年轻,LDQoL评分更低,并且在当前焦虑、抑郁和饮酒问题症状上得分更高。在多变量分析中,单独使用药物治疗或同时使用行为和药物治疗的几率(与不使用相比)随着年龄的增长或LDQoL的升高而降低,而在有焦虑/抑郁病史的患者中则更高。对于过去12个月的治疗使用情况,年龄越大,几率越低,而目前有临床显著焦虑/抑郁或饮酒问题的患者,几率越高。结论:年轻或有焦虑/抑郁和饮酒问题的酒精相关性肝硬化患者更有可能使用AUD治疗。为了提高AUD治疗的利用率,有针对性地向不太可能接受治疗的患者推广,并提供ALD和AUD综合治疗是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信